Financials

  • Market Capitalization 1.8 B
  • Employee 110
  • Founded 2024
  • CEO N/A
  • Website www.inhibrx.com
  • Headquarter Delaware, United States
  • FIGI BBG01MS5Q9G3
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-8.74
Rapporto prezzo/fatturato
941.13

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
2070
SEPN
Septerna, Inc. - Common Stock
38.92 USD-3.83%-4.40%+14.57%+76.83%1.82 B USD
2075
FTRE
Fortrea Holdings Inc. - Common Stock
18.98 USD+0.64%+3.26%-3.11%+94.47%1.80 B USD
2082
NTLA
Intellia Therapeutics, Inc. - Common Stock
12.81 USD-2.29%-0.70%+18.94%-6.63%1.80 B USD
2085
RXRX
Recursion Pharmaceuticals, Inc. - Class A Common Stock
3.35 USD-2.62%-4.56%+10.56%-30.93%1.79 B USD

Notizie